NewsEvents

Your Yourlocation: Home > Tiotropium bromide(136310-93-5) combined with glucocorticoid inhalation therapy can significantly improve the ACOS patients with pulmonary function and clinical symptoms

Clinical symptoms, pathophysiology and genetics of deepening, more features will be gradually clarified. Long-term anticholinergic drug tiotropium bromide(136310-93-5) in the inhaled glucocorticoid therapy, based on the effective improvement of ACOS patients with pulmonary function. The aim of this study was to investigate the effect of tiotropium plus inhaled glucocorticoids on ACOS in patients without long-acting β2-agonist therapy, compared with tiotropium alone and inhaled corticosteroids.

The patients were divided into tiotropium bromide(136310-93-5) group and budesonide powder inhalation group: 16 males and 4 females, aged 40-75 years (mean, 50 ± 7.26 years). The budesonide powder inhalation group: 16 males and 4 females with a mean age of (46 ± 5.64) years; mean age (57 ± 5 years) 10.28) years. There were no statistically significant differences in age, sex, course of disease, asthma control score, ACT score and lung function among the three groups. This study was approved by the hospital ethics committee, the patient informed consent, and signed informed consent.

Three groups have similar adverse reactions, but are relatively minor or can be prevented by the corresponding treatment. The most frequent adverse events in the tiotropium group (A), tiotropium and budesonide (C) were dry mouth, usually mild, and the reaction disappeared with continued treatment. The most common side effects of budesonide powder inhalation (B) were hoarseness and oral candidiasis, while adverse reactions such as sinusitis, constipation, palpitations, irritability and acute urinary retention were rarely seen through the above treatment and treatment cycles.

Through clinical observation, we believe that tiotropium bromide(136310-93-5) combined with glucocorticoid inhalation therapy can significantly improve the ACOS patients with pulmonary function and clinical symptoms, reduce the number of acute attacks, the effect is better than single-dose glucocorticoid inhalation and single use tiotropium bromide(136310-93-5) inhalation therapy, and can improve the short-term prognosis, and does not increase adverse drug reactions. However, considering the limited number of cases observed in this study, and for single-center study, still need large sample, multi-center, long-term follow-up study to further explore the prospective.

Address: TEL:0531-82375879 Tiotropium Bromide
© Copyright(C)2014 JINAN DEXINJIA BIO & TECH CO., LTD All Rights Reserved